Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LB1901

Cell therapy (CAR-T) · Kills target cells, directed at CD4 · developed by Legend Biotech USA

Phase 1 Most advanced trial (none active)
LEGN Developer
1 Registered trials

What is LB1901?

LB1901 is an autologous CAR-T cell therapy made from a patient's own T-lymphocytes, transduced with a lentiviral vector to express a chimeric antigen receptor targeting CD4. The modified cells bind CD4-expressing tumor cells and selectively kill them. It is studied in T-cell lymphomas, including peripheral and cutaneous forms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
CD4 (antigen)
Mechanism
Kills target cells, directed at CD4
Therapy area
Oncology
Developer
Legend Biotech USA Inc (LEGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04712864 Phase 1 T-Cell Lymphoma Unknown LEGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cutaneous T-Cell Lymphoma RecurrentCutaneous T-Cell Lymphoma RefractoryPeripheral T-Cell Lymphoma RecurrentPeripheral T-Cell Lymphoma RefractoryT-Cell Lymphoma

Other drugs acting on CD4

More from Legend Biotech USA

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LEGN page.

Follow LEGN, the company behind LB1901

See LEGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LEGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.